{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T03:38:51Z","timestamp":1791344331633,"version":"4.3.1"},"reference-count":36,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,3,1]],"date-time":"2017-03-01T00:00:00Z","timestamp":1488326400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2017,3]]},"DOI":"10.1016\/j.ejmech.2017.02.019","type":"journal-article","created":{"date-parts":[[2017,2,11]],"date-time":"2017-02-11T03:01:38Z","timestamp":1486782098000},"page":"41-52","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":33,"special_numbering":"C","title":["Synthesis of new heterocyclic compounds based on pyrazolopyridine scaffold and evaluation of their neuroprotective potential in MPP + -induced neurodegeneration"],"prefix":"10.1016","volume":"129","author":[{"given":"Jabrane","family":"Jouha","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammed","family":"Loubidi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jamila","family":"Bouali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salha","family":"Hamri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abderrafia","family":"Hafid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franck","family":"Suzenet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G\u00e9rald","family":"Guillaumet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taner","family":"Dagc\u0131","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mostafa","family":"Khouili","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5222-7555","authenticated-orcid":false,"given":"Fadime","family":"Ayd\u0131n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luciano","family":"Saso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G\u00fcliz","family":"Armagan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejmech.2017.02.019_bib1","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1016\/S0960-894X(03)00034-9","article-title":"1H-Pyrazolo[3,4-b]pyridine inhibitors of cyclin-dependent kinases","volume":"13","author":"Misra","year":"2003","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2017.02.019_bib2","doi-asserted-by":"publisher","first-page":"2405","DOI":"10.1016\/S0960-894X(03)00381-0","article-title":"1H-Pyrazolo[3,4-b]pyridine inhibitors of cyclin-dependent kinases: highly potent 2,6-difluorophenacyl analogues","volume":"13","author":"Misra","year":"2003","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2017.02.019_bib3","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1016\/j.tips.2004.07.006","article-title":"Pharmacological inhibitors of glycogen synthase kinase 3","volume":"25","author":"Meijer","year":"2004","journal-title":"Trends Pharm. Sci."},{"key":"10.1016\/j.ejmech.2017.02.019_bib4","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1002\/jhet.5570100607","article-title":"Antituberculous compounds. XXVIII. Synthesis of pyrazolopyridines","volume":"10","author":"Sekikawa","year":"1973","journal-title":"J.\u00a0Heterocycl. Chem."},{"key":"10.1016\/j.ejmech.2017.02.019_bib5","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1016\/j.farmac.2005.05.002","article-title":"Synthesis and antibacterial activity of 1H-pyrazolo[3,4-b]pyrazine and -pyridine derivatives","volume":"60","author":"Foks","year":"2005","journal-title":"Il Farm."},{"key":"10.1016\/j.ejmech.2017.02.019_bib6","doi-asserted-by":"publisher","first-page":"1845","DOI":"10.1016\/j.bmc.2004.01.040","article-title":"Synthesis, antimicrobial activity and conformational analysis of novel substituted pyridines: BF3-promoted reaction of hydrazine with 2-alkoxy pyridines","volume":"12","author":"Goda","year":"2004","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2017.02.019_bib7","first-page":"238","article-title":"Synthesis, characterization and pharmacological evaluation of some novel Schiff bases containing 1H-pyrazolo[3,4-b]pyridine moiety","volume":"3","author":"Kundariya","year":"2011","journal-title":"Int. J. Chem. Tech. Res."},{"key":"10.1016\/j.ejmech.2017.02.019_bib8","doi-asserted-by":"publisher","first-page":"3055","DOI":"10.1016\/S0960-894X(03)00645-0","article-title":"6-Aryl-pyrazolo[3,4-b]pyridines: potent inhibitors of glycogen synthase kinase-3 (GSK-3)","volume":"13","author":"Witherington","year":"2003","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2017.02.019_bib9","doi-asserted-by":"publisher","first-page":"1577","DOI":"10.1016\/S0960-894X(03)00134-3","article-title":"5-Aryl-pyrazolo[3,4-b]pyridines: potent inhibitors of glycogen synthase kinase-3 (GSK-3)","volume":"13","author":"Witherington","year":"2003","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2017.02.019_bib10","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1016\/S0960-894X(01)00073-7","article-title":"NO-independent stimulators of soluble guanylate cyclase","volume":"11","author":"Straub","year":"2001","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2017.02.019_bib11","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1111\/j.1527-3458.1998.tb00074.x","article-title":"The Pharmacology and Mechanism of action of zolpidem","volume":"4","author":"Sanger","year":"1998","journal-title":"CNS Drug Rev."},{"key":"10.1016\/j.ejmech.2017.02.019_bib12","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/S1471-4892(01)00008-X","article-title":"GABA(A)-receptor subtypes: a new pharmacology","volume":"1","author":"Mohler","year":"2001","journal-title":"Curr. Opin. Pharmacol."},{"key":"10.1016\/j.ejmech.2017.02.019_bib13","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1038\/nature01808","article-title":"Analgesia and hyperalgesia from GABA-mediated modulation of the cerebral cortex","volume":"424","author":"Jasmin","year":"2003","journal-title":"Nature"},{"key":"10.1016\/j.ejmech.2017.02.019_bib14","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1124\/mol.61.4.861","article-title":"Molecular dissection of benzodiazepine binding and allosteric coupling using chimeric \u03b3-aminobutyric acidA receptor subunits","volume":"61","author":"Thompson","year":"2002","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.ejmech.2017.02.019_bib15","doi-asserted-by":"publisher","first-page":"4998","DOI":"10.1016\/j.bmcl.2005.08.006","article-title":"Pyrazolopyridinones as functionally selective GABAA ligands","volume":"15","author":"Blackaby","year":"2005","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2017.02.019_bib16","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1038\/35040009","article-title":"Apoptosis in neurodegenerative disorders","volume":"1","author":"Mattson","year":"2000","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.ejmech.2017.02.019_bib17","doi-asserted-by":"crossref","first-page":"125","DOI":"10.3233\/JAD-132738","article-title":"Apoptosis and oxidative stress in neurodegenerative diseases","author":"Radi","year":"2014","journal-title":"J.\u00a0Alzheimer's, Dis."},{"key":"10.1016\/j.ejmech.2017.02.019_bib18","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1111\/j.1749-6632.2003.tb07476.x","article-title":"The 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model: a tool to explore the pathogenesis of Parkinson's disease","volume":"991","author":"Przedborski","year":"2003","journal-title":"Ann. N. Y. Acad. Sci."},{"issue":"Suppl 3","key":"10.1016\/j.ejmech.2017.02.019_bib19","article-title":"Limitations of current Parkinson's disease therapy","volume":"53","author":"Rascol","year":"2003","journal-title":"Ann. Neurol."},{"issue":"2","key":"10.1016\/j.ejmech.2017.02.019_bib20","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/S0306-9877(03)00318-9","article-title":"Two faces of L-DOPA : benefits and adverse side effects in the treatment of encephalitis lethargica, Parkinson's disease, multiple sclerosis and amyotrophic lateral sclerosis","volume":"62","author":"Foster","year":"2004","journal-title":"Med. Hypotheses"},{"issue":"4","key":"10.1016\/j.ejmech.2017.02.019_bib21","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1016\/j.parkreldis.2007.09.007","article-title":"Dopamine dysregulation syndrome, addiction and behavioral changes in Parkinson's disease","volume":"14","author":"Merims","year":"2008","journal-title":"Park. Relat. Disord."},{"key":"10.1016\/j.ejmech.2017.02.019_bib22","doi-asserted-by":"publisher","first-page":"1177","DOI":"10.1002\/jhet.199","article-title":"Synthesis of new compounds containing the pyrazolo[3,4-b]pyridine-3-one subunit","volume":"46","author":"Fadel","year":"2009","journal-title":"J.\u00a0Heterocycles. Chem."},{"key":"10.1016\/j.ejmech.2017.02.019_bib23","first-page":"240","article-title":"Synthesis of new pyrazolo[3,4-b]pyridin-3-ones and pyrazolo[1,5-a]pyrimidin-2(1H)-one and study of the pyrazolic nitrogen reactivity","author":"Fadel","year":"2011","journal-title":"ARKIVOC (ii)"},{"issue":"Suppl.\u00a01","key":"10.1016\/j.ejmech.2017.02.019_bib24","first-page":"35","article-title":"Mechanisms of MPTP toxicity","volume":"13","author":"Przedborski","year":"1998","journal-title":"Mov. Disord."},{"key":"10.1016\/j.ejmech.2017.02.019_bib25","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/0014-5793(90)81315-F","article-title":"Mechanism of the neurotoxicity of MPTP","volume":"274","author":"Singer","year":"1990","journal-title":"FEBS Lett."},{"key":"10.1016\/j.ejmech.2017.02.019_bib26","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1016\/j.ejcb.2008.03.003","article-title":"Kynurenic acid attenuates MPP(+)-induced dopaminergic neuronal cell death via a Bax-mediated mitochondrial pathway","volume":"87","author":"Lee","year":"2008","journal-title":"Eur. J. Cell Biol."},{"issue":"5","key":"10.1016\/j.ejmech.2017.02.019_bib27","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1002\/(SICI)1097-4547(19990301)55:5<620::AID-JNR9>3.0.CO;2-S","article-title":"Characterization and time course of MPP+ -induced apoptosis in human SH-SY5Y neuroblastoma cells","volume":"55","author":"Fall","year":"1999","journal-title":"J.\u00a0Neurosci. Res."},{"key":"10.1016\/j.ejmech.2017.02.019_bib28","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.1126\/science.275.5303.1129","volume":"275","author":"Yang","year":"1997","journal-title":"Science"},{"key":"10.1016\/j.ejmech.2017.02.019_bib29","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1016\/S0955-0674(00)00110-1","article-title":"Bax, Bid and the permeabilization of the mitochondrial outer membrane in apoptosis","volume":"12","author":"Crompton","year":"2000","journal-title":"Curr. Opin. Cell. Biol."},{"key":"10.1016\/j.ejmech.2017.02.019_bib30","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/S0301-0082(01)00003-X","volume":"65","author":"Blum","year":"2001","journal-title":"Prog. Neurobiol."},{"key":"10.1016\/j.ejmech.2017.02.019_bib31","first-page":"919058","article-title":"Neuroprotective effects of alpha-mangostin on MPP(+)-Induced apoptotic cell death in neuroblastoma SH-SY5Y cells","author":"Janhom","year":"2015","journal-title":"J.\u00a0Toxicol."},{"key":"10.1016\/j.ejmech.2017.02.019_bib32","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1016\/j.ejmech.2016.06.036","article-title":"Avarol derivates as competitive AChE inhibitors, non hepatotoxic and neuroprotective agents for Alzheimer's disease","volume":"122","author":"Tommonaro","year":"2016","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2017.02.019_bib33","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1016\/j.ejmech.2016.07.010","article-title":"Design of a novel thiophene inhibitor of 15-lipoxygenase1 with both antiinflammatory and neuroprotective properties","volume":"122","author":"Eleftheriadis","year":"2016","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2017.02.019_bib34","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1016\/j.ejmech.2016.05.055","article-title":"New cinnamic \u2013N-benzylpiperidine and cinnamic \u2013N,N- dibenzyl(N-methyl)amine hybrids as Alzheimer-directed multitarget drugs with antioxidant, cholinergic, neuroprotective and neurogenic properties","volume":"122","author":"Estrada","year":"2016","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2017.02.019_bib35","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1096\/fj.04-1551fje","article-title":"Glycogen synthase kinase 3beta (GSK3beta) mediates 6-hydroxydopamine-induced neuronal death","volume":"18","author":"Chen","year":"2004","journal-title":"FASEB J."},{"key":"10.1016\/j.ejmech.2017.02.019_bib36","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1007\/s12031-013-0075-8","article-title":"Neuroprotective effect of CNB-001, a novel pyrazole derivative of curcumin on biochemical and apoptotic markers against rotenone-induced SK-N-SH cellular model of Parkinson's disease","volume":"51","author":"Jayaraj","year":"2013","journal-title":"J.\u00a0Mol. Neurosci."}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523417300843?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523417300843?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,9,18]],"date-time":"2019-09-18T11:40:05Z","timestamp":1568806805000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523417300843"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,3]]},"references-count":36,"alternative-id":["S0223523417300843"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2017.02.019","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2017,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Synthesis of new heterocyclic compounds based on pyrazolopyridine scaffold and evaluation of their neuroprotective potential in MPP+-induced neurodegeneration","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2017.02.019","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}